TRED-HF Recovery Relapse Prediction Model
Clinical context review
Enter available baseline characteristics to create a structured review. This tool does not calculate a validated relapse score.
About TRED-HF and relapse
TRED-HF was a pilot randomized trial of phased withdrawal of pharmacological treatment in selected patients with previously dilated cardiomyopathy whose left ventricular function had recovered. In the original trial, approximately 40% of participants assigned to withdraw treatment relapsed within six months.
In long-term follow-up, 33 of 51 participants (65%) experienced relapse over a median follow-up of six years. The estimated five-year relapse rate from enrolment was 61% (95% CI 45–73%). These are cohort-level observations, not a personalized estimate for an individual patient.
Relapse definition used in follow-up
The long-term report defined relapse as a reduction in LVEF of at least 10 percentage points to below 50%, doubling of NT-proBNP to above 400 ng/L, or clinical features of heart failure. Criteria and protocol details differed across trial and post-trial follow-up; refer to the original publication for exact definitions at each phase.
Clinical use
- Do not interpret recovery of LVEF as proof of permanent cure.
- Do not use this page to estimate an individual patient's probability of relapse or to support medication withdrawal.
- Continue guideline-directed therapy unless a treating specialist identifies a compelling individualized reason to modify it.
- Consider ongoing clinical review, cardiac imaging and natriuretic peptide monitoring according to the patient's clinical context.
Evidence and limitations
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.